Viridian Therapeutics Reports Positive Phase 1 Results for VRDN-008
Viridian said Phase 1 results for VRDN-008 support its potential best-in-class profile with every-eight-week subcutaneous dosing.
Story updates
12:02:27 PM UTC
SquawkNews
Viridian reported positive Phase 1 results for VRDN-008, evaluated in healthy volunteers, and plans to begin registrational development in myasthenia gravis in mid-2027, pending regulatory feedback. The release described every-8-week subcutaneous dosing as a potential profile.Material DetailsContex…